Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2011

Open Access 01-12-2011 | Review

Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer

Authors: Rabia Faridi, Amreen Zahra, Khalida Khan, Muhammad Idrees

Published in: Virology Journal | Issue 1/2011

Login to get access

Abstract

Human Papillomavirus (HPV) is the most common cause of cervical cancer. Cervical cancer being the second most common cancer after lung cancer, affecting women of different age groups; has a prevalence of about 20% in young sexually active women. Among different types of HPV, HPV16 the major strain causing this cancer and is sexually transmitted had been unnoticed for decades. Keeping in mind the multiple risk factors related with cervical cancer such as early age sexual activities, teenage pregnancies, smoking, use of oral contraceptives, having multiple sex partners, hormone replacement therapies and various other unknown factors lead to the onset of the disease. Awareness for various diagnostic procedures such as Pap smears screening prove to be an effective way in eradicating the oncogenic potential of HPV.
Appendix
Available only for authorised users
Literature
1.
Review of Medical Microbiology and Immunology 10th edition. Edited by: Warren Levinson. Mc GrawHill; 2008:270-275.
2.
Molecular biologists for Oncologists 2nd edition. Edited by: Yarnold JR, Stratton MR, McmMillan TJ. Chapman and Hall; 1996:83-88.
3.
Khan S, Jaffer NN, Khan MN, Rai MA, Shafiq M, Ali A, Pervez S, Khan N, Aziz A, Ali SH: Human papillomavirus subtype 16 is common in Pakistaniwomen with cervical carcinoma. Int J Infect Dis 2007, 11: 313-317. 10.1016/j.ijid.2006.06.007CrossRefPubMed
4.
Yasmeen A, Alachkar A, Dekhil H, Gambacorti-Passerini C, Al Moustafa AE: Locking Src/AblTyrosine Kinase activities regulate cell Differentiation and Invasion of Human cervical cancer cells expressing E 6 /E 7 oncoproteins of High-risk HPV. J Oncol 2010, 2010: 10.CrossRef
5.
Stone MK, Karem LK, Sternberg RM, McQuillan MG, Poon DA, Unger RA, Reeves CW: Seroprevalence of human papillomavirus type16 infection in the United States. J Infect Dis 2002, 186: 1396-1402. 10.1086/344354CrossRefPubMed
6.
Porass C, Bennett C, Safaeian M, Coseo S, Rodriguez AC, Gonzaález P, Hutchinson M, Jimenez S, Sherman ME, Wacholder S, Solomon D, Doorn Leen-Jan V, Bougelet C, Quint W, Schiffman M, Herrero R, Hildeshein A: Determinants of Seropositivity among HPV16/18DNA positive young women. BMC Infect Dis 2010, 10: 238.
7.
Conway MJ, Alam S, Ryndock EJ, Cruz L, Christensen ND, Roden RBS, Meyers C: Tissue-spanning redox gradient-dependant assembly of native human papilloma virus type 16 virions. J virol 2009, 83: 10515-10526. 10.1128/JVI.00731-09PubMedCentralCrossRefPubMed
8.
Microbiology and molecular biology reviews 2004,68(2):1092-2172.
9.
Gao P, Zheng J: High-risk HPV E 5 - induced cell fusion a critical initiating event in the early stage of HPV-associated cervical cancer. J Virol 2010, 7: 238. 10.1186/1743-422X-7-238CrossRef
10.
Nariseuva Saito M, et al.: Basic mechanisms of High-risk human papilloma virus induced carcinogenesis. Cancer Science 2007, 98: 1505-1511. 10.1111/j.1349-7006.2007.00546.xCrossRef
11.
Tsai TC, Chen SL: The biochemical and biological functions of human papilloma virus type16 E 5 protein. Archieves Virology 2003, 148: 1445-1453. 10.1007/s00705-003-0111-zCrossRef
12.
Zerfass D, et al.: Sequential activation of cyclin Eand cyclin Agene expression by human papilloma virus type 16E 7 through sequences necessary for transformation. J Virol 1995, 69: 6389-6399.PubMedCentralPubMed
13.
Gagnon D, Joubert S, Senechal H, Fradet-Turcotte A, Torre S, Archambault J: Proteasomal degradation of the papillomavirus E 2 protein is inhibited by overexpression of bromodomain containing protein 4. J Virol 2009, 83: 4127-4139. 10.1128/JVI.02468-08PubMedCentralCrossRefPubMed
14.
Muller Schiffmann A, Beckmann J, Steger G: The E 6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanisms. J Virol 2006, 80: 8718-8728. 10.1128/JVI.00250-06PubMedCentralCrossRefPubMed
15.
Lace MJ, Anson JR, Thomas GS, Turek LP, Haugen TH: The E 8 {wedge}E 2 gene product of human papillomavirus type 16 represses early transcription of replication but is dispensable for viral plasmid persistence in Keratinocytes. J Virol 2008, 82: 10841-10853. 10.1128/JVI.01481-08PubMedCentralCrossRefPubMed
16.
Incassati A, Patel D, McCance DJ: Induction of Tetraploidy through loss of p53 and upregulation of Plk1by human papillomavirus type 16 E 6 . Oncogene 2006, 25: 2444-2451. 10.1038/sj.onc.1209276CrossRefPubMed
17.
Darnell GA, Schroder WA, Antalis TM, Lambley E, Major L, Gardner J, Birell G, Suhrbier A: Human papilloma virus E 7 requires the protease calpain to degrade the retinoblastoma protein. J Biol Chem 2007, 282: 37492-37500. 10.1074/jbc.M706860200CrossRefPubMed
18.
Zhang B, Chen W, Roman A: The E 7 proteins of low and high-risk human papilloma viruses share the ability to target the pRb family member p130 for degradation. Proc Natl Acad Sci 2006, 103: 437-442. 10.1073/pnas.0510012103PubMedCentralCrossRefPubMed
19.
Dyson N, Howley PM, K M, Harlow E: The human papilloma virus E 7 oncoprotein is able to bind to the retinoblastomagene product. Science 1987, 243: 934-937.CrossRef
20.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschin S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grdae cervical lesions:a meta analysis update. Int J Cancer 2007, 3: 621-632.CrossRef
21.
Stanely M: Immune responses to human papillomavirus. Vaccine 2006,24(suppl1):S10-16.
22.
de Villiers EM: Relation ship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 2003, 103: 705-708. 10.1002/ijc.10868CrossRefPubMed
23.
Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM: Sensitivity of the cervical transformation zone to estrogen induced squamous carcinogenesis. Cancer Research 2000, 60: 1267-1275.PubMed
24.
Paavonen T, Andersson LC, Adlercreutz H: Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen stimulated cultures. J E M 1981, 154: 1935-1945. 10.1084/jem.154.6.1935CrossRef
25.
Hughes GC, Clark EA: Regulation of Dendritic cells by female sex steroids: relevance to immunity and auto immunity. Auto immunity 2007, 40: 470-481.
26.
Langlois MR, Delanghe JR: Biological and clinical significance of haptoglobin in human. Eur J Clin Chem 1996, 42: 1589-1600.
27.
Quaye IK: Haptoglobin inflammation and disease. Trans R soc trop medi hyg 2008, 102: 735-742. 10.1016/j.trstmh.2008.04.010CrossRef
28.
Vilerberghe HV, Langlois M, Delanghe J: Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin chimica Acta 2004, 345: 35-42. 10.1016/j.cccn.2004.03.016CrossRef
29.
Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP: Haptoglobim genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free haemoglobin. Artherosclerosis 2007, 191: 48-53. 10.1016/j.atherosclerosis.2006.04.032CrossRef
30.
Bottini N, Gimelfarb A, Gloria-Bottini F, La Torre M, Lucarelli P, Lucarini N: Haptoglobin genotype and natural fertility in humans. Fertility and a Sterility 1999, 72: 293-296. 10.1016/S0015-0282(99)00210-1CrossRef
31.
Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR: Prevalence of HPV infection among men: Asystematic review of the literature. J infect dis 2006, 1994: 1044-1057.CrossRef
32.
Ho Gloria YF, Studentsov YY, Bierman R, D Burk R: Natural history of human papillomavirus type 16 virus like particle antibodies in young women. Cancer Epidemiology, Biomarkers and Prevention 2004, 13: 110-116. 10.1158/1055-9965.EPI-03-0191CrossRefPubMed
33.
Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD: The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337: 76-84. 10.1016/j.virol.2005.04.002CrossRefPubMed
34.
Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, Jung KY, Kim HH, Park UD, Cha HS, Park S, Touzé A, Muñoz N, Snijders PJ, Meijer CJ, Coursaget P, Franceschi S: Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003, 103: 413-421. 10.1002/ijc.10825CrossRefPubMed
35.
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Eng J Med 2003, 348: 518-527. 10.1056/NEJMoa021641CrossRefPubMed
36.
Müller-Schiffmann A, Beckmann J, Steger J: The E 6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanism. J virol 2006, 80: 8718-8728. 10.1128/JVI.00250-06PubMedCentralCrossRefPubMed
37.
Herdman MT, Pett MR, Roberts I, Alazawi WO, Teschendorff AE, Zhang XY, Stanley MA, Coleman N: Interferon-{beta}treatment of cervical keratinocytes naturally infected with human papillomavirus16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 2006, 27: 2341-2353. 10.1093/carcin/bgl172CrossRefPubMed
38.
Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV: The casual relationship between human papillomavirus and cervical cancer. J clin Pathol 2002,55(4):244-265. 10.1136/jcp.55.4.244PubMedCentralCrossRefPubMed
39.
Frazer IH: Interaction of human papillomavirus with the host immune system:a well evolved relationship. Virology 2009,384(2):410-414. 10.1016/j.virol.2008.10.004CrossRefPubMed
40.
Darnell GA, Schroder WA, Antalis TM, Lambley E, Major L, Gardner J, Birrell G, Cid-Arregui A, Suhrbier A: Human papillomavirus E 7 requires the protease Calpain to degrade the Retinoblastoma Protein. J Bio Chem 2007, 282: 37492-37500. 10.1074/jbc.M706860200CrossRef
41.
Patrick DR, Oliff A, Heimbrook DC: Identification of a novel Retinoblastoma gene product binding site on human papillomavirus type16 E 7 protein. J Bio Chem 1994,269(9):6842-6850.
42.
Chung SH, Franceschi S, Lambert PF: Estrogen and ER-α:Culprits in cervical cancer. The Cell 2010, 21: 504-511.
43.
International Collaboration of Epidemiological studies of cervical cancer cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006, 119: 1108-112.CrossRef
44.
International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S: Cervical cancer and hormonal contraceptives:collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007, 370: 1609-1621.CrossRef
45.
Curado MP, Edward BK, Shin HR, Storm H: Cancer incidence in five continents. 29th Meeting of the International Association of Cancer Registries. 2007 September 17. Ljubliana, Slovenia
46.
Baniyash M: Chronic inflammation, immunosupression in cancer:new insights and outlook. Seminar cancer biology 2006,16(1):80-88. 10.1016/j.semcancer.2005.12.002CrossRef
47.
Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA: Seminal plasma differentially regulates inflammatory cytokine gene expreesion in human cervical and vaginal epithelial cells. Mol hum rep 2007,13(7):491-501. 10.1093/molehr/gam028CrossRef
48.
Kelly RW: Immunosuppressive mechanism in semen: Implications for contraceptions. Hum Rep 1995,10(7):1686-1693.
49.
Sales KJ, Katz AA, Millar RP, Jabbour HN: Seminal plasma activates cyclooxygenase-2 and prostaglandin E2 receptor expression and signalling in cervical adenocarcinoma cells. Mol Hum Rep J 2002,8(12):1065-1070. 10.1093/molehr/8.12.1065CrossRef
50.
Herfs M, Herman L, Hubert P, Minner F, Arafa M, Roncarati P, Henrotin Y, Boniver J, Delvenne P: High expression of PGE2 enzymatic pathways in cervical (Pre) neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunology J 2009,58(4):603-614.CrossRef
51.
Hung PH, Froenicke L, Lin CY, Lyons LA, Miller MG, Pinkerton KE, VandeVoort CA: Effects of environmental tobacco smoke in vivo on rhesus monkey semen quality, sperm function, sperm metabolism. Reproductive Toxicology 2009,27(2):140-14. 10.1016/j.reprotox.2008.12.007CrossRefPubMed
52.
Schiffman M, Castle EP, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 2007,370(9590):890-907. 10.1016/S0140-6736(07)61416-0CrossRefPubMed
53.
Wellings K, Collumbien M, Slaymaker E, Singh S, Hodges Z, Patel D, Bajo N: Sexual behaviour in context:a global perspective. Lancet 2006,368(9548):1706-1728. 10.1016/S0140-6736(06)69479-8CrossRefPubMed
54.
Baay MF, Quint WG, Koudstaal J, Hollema H, Duk JM, Burger MP, Stolz E, Herbrink P: Comprehensive study of several general and type specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin embedded cervical carcinomas. J Clin Microbiol 1996, 34: 745-747.PubMedCentralPubMed
55.
Van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B: Highly effengtive detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad spectrum and type specific PCR. J Clin Microbiol 2006, 44: 3292-3298. 10.1128/JCM.00539-06PubMedCentralCrossRefPubMed
56.
Venuti A, Badaracco G, Sedati A, Carbini R, Marcante ML: Determinants of HPV types 16,18 infections in the lower female genital tract in an Italian population. Eur J Gynaecol Oncol 2004, 15: 205-10.
57.
Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, Lorincz A, Dalby DM, Janjusevic V, Keller JL: Prevalence and predictors of HPV infection in women in Ontario, Canada. Survey of HPV in Ontario women (SHOW) Group. Can Med Assosc J 2000, 163: 503-508.
58.
Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A, Survey of HPV in Ontario Women Group: Incidence, Clearannce and predictors of human pappilomavirus infection in women. Can Med Assosc J 2003, 168: 421-425.
59.
Shields TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RG, Studentsov YY, McAdams M, Schiffman M: A case-control study of risk factors for invasive cervical cancer among US women exposed to oncogenic types of human pappilomavirus. Cancer Epidemiology Biomarkers 2004, 13: 1574-1582.
60.
Vaccarella S, Franceschi S, Herrero R, Muñoz N, Snijders PJ, Clifford GM, Smith JS, Lazcano-Ponce E, Sukvirach S, Shin HR, de Sanjosé S, Molano M, Matos E, Ferreccio C, Anh PT, Thomas JO, Meijer CJ, IARC HPV Prevalence Surveys Study Group: Sexual bahaviour, condom use, and human pappilomavirus: Pooled analysis of the IARC human pappilomavirus prevalence surveys. Cancer Epidemiology Biomarkers 2006, 15: 326-333. 10.1158/1055-9965.EPI-05-0577CrossRef
61.
Almonte M, Albero G, Molano M, Carcamo C, García PJ, Pérez G: Risk factors for human papillomavirus exposure and co factors for cervical cancer in Latin America and the Caribbean. Vaccine 2008, 26: L16-L36.CrossRefPubMed
62.
Herbert J, Coffin J: Reducing patient risk for human papillomavirus infection and cervical cancer. J Am Osteopathic Assoc 2008, 108: 65-70.
63.
Lenselink CH, Melchers WJ, Quint WG, Hoebers AM, Hendriks JC, Massuger LF, Bekkers RL: Sexual behaviour and HPV infections in 18 to 29 year old women in the pre vaccine era in the Netherlands. PLos One 2008, 3: 3743. 10.1371/journal.pone.0003743CrossRef
64.
Chan PK, Ho WC, Wong MC, Chang AR, Chor JS, Yu MY: Epidemilogical risk profile of infection with different groups of HPV. J Med Virology 2009, 81: 1635-1644. 10.1002/jmv.21575CrossRef
65.
66.
deVilliers EM: Classification of papillomaviruses. J Virology 2004, 324: 17-27. 10.1016/j.virol.2004.03.033CrossRef
67.
Stanley M: Immune responses to human pappilomavirus. Vaccine 2006, (S):16-22.
68.
Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD: Epidemiologic profile of type specific human pappilomavirus infection and cervical neoplasia in Guanacaste, costa Rica. J Infect Dis 2005, 191: 1796-807. 10.1086/428850CrossRefPubMed
69.
Muñoz N, Kato I, Bosch FX, Eluf-Neto J, De Sanjosé S, Ascunce N, Gili M, Izarzugaza I, Viladiu P, Tormo MJ, Moreo P, Gonzalez LC, Tafur L, Walboomers JM, Shah KV: Risk factors for HPV DNA detection in middleaged women. Sexually Transmitted Diseases 1996, 23: 504-10. 10.1097/00007435-199611000-00012CrossRefPubMed
70.
Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR: Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006, 194: 1044-57. 10.1086/507432CrossRefPubMed
71.
Stanley M: A practitioner's guide to understanding immunity to human papillomavirus. Am J Obstet Gynecol 2009, 4: 2-7.
72.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group: Efficacy of a bivalent L1 virus like particle vaccine in prevention of infection with HPV types 16 and 18 in young women: A randomized controlled trial. Lancet 2004, 364: 1757-1765. 10.1016/S0140-6736(04)17398-4CrossRefPubMed
73.
Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, HPV Vaccine Study group: Sustained efficacy upto 4.5 years of a bivalent L1 virus like particle vaccine against HPV types 16 and 18: Follow up from a randomized controlled trial. Lancet 2006, 367: 1247-1255. 10.1016/S0140-6736(06)68439-0CrossRefPubMed
74.
Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E: Prophylactic quadrivalent human papillomavirus (types 6,11,16 and 18) L1 virus like particle vaccine in young women:A randomised double blind placebo-controlled multicentre phase II efficacy trial. Lancet 2005, 6: 271-278. 10.1016/S1470-2045(05)70101-7CrossRefPubMed
75.
Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow up. Br J Cancer 2006, 95: 1459-1466. 10.1038/sj.bjc.6603469PubMedCentralCrossRefPubMed
76.
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group, Greenacre M: Efficay of human papillomavirus (HP oncogenic HPV types (PATRICIA): Final analysis of a double-blind randomised study in young women. Lancet 2009, 374: 301-314. 10.1016/S0140-6736(09)61248-4CrossRefPubMed
77.
Bos AB, Rebolj M, Habbema JD, van Ballegooijen M: Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer 2006, 119: 2372-5. 10.1002/ijc.22114CrossRefPubMed
78.
Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, Babovć M, van Ballegooijen M, Helmerhorst TJ, Meijer CJ: Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 2007, 120: 1505-10. 10.1002/ijc.22484CrossRefPubMed
79.
Anttila A, Nieminen P: Cervical cancer screening programme in Finland with an example on implementing alternative screening methods. Collegium Antropologicum 2007, 31: 17-22.PubMed
80.
Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M, Weiderpass E: Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004, 91: 935-41.PubMedCentralPubMed
81.
Van Ballegooijen M, van den Akker-van Marle E, Patnick J, Lynge E, Arbyn M, Anttila A, Ronco G, Dik J, Habbema F: Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur Journal of Can 2000, 36: 2177-88. 10.1016/S0959-8049(00)00330-0CrossRef
82.
Peto J, Gilham C, Fletcher O, Matthews FE: The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004, 364: 249-56. 10.1016/S0140-6736(04)16674-9CrossRefPubMed
83.
Sawaya GF, Grimes DA: New technologies in cervical cytology screening: a word of caution. Obstet Gynecol 1999, 94: 307-10. 10.1016/S0029-7844(99)00289-6CrossRefPubMed
84.
Kinney W, Sung HY, Kearney KA, Miller M, Sawaya G, Hiatt RA: Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC). Gynecol Oncol 1998, 71: 428-30. 10.1006/gyno.1998.5135CrossRefPubMed
85.
Sasieni PD, Cuzick J, Lynch-Farmery E: Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 1996, 73: 1001-5. 10.1038/bjc.1996.196PubMedCentralCrossRefPubMed
Metadata
Title
Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer
Authors
Rabia Faridi
Amreen Zahra
Khalida Khan
Muhammad Idrees
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2011
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-8-269

Other articles of this Issue 1/2011

Virology Journal 1/2011 Go to the issue

Methodology

Site directed biotinylation of filamentous phage structural proteins

Research

Colour break in reverse bicolour daffodils is associated with the presence of Narcissus mosaic virus

Research

Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein

Research

Active hepatitis C infection and HCV genotypes prevalent among the IDUs of Khyber Pakhtunkhwa

Research

Enterovirus 71 induces degradation of TRIM38, a potential E3 ubiquitin ligase

Research

Human bocavirus (HBoV) in children with respiratory tract infection by enzyme linked immunosorbent assay (ELISA) and qualitative polymerase chain reaction (PCR)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits